Latest Strategic Investment News

Page 12 of 105
Corporate Travel Management reports a resilient first half of FY26 with strong client retention and progress on UK remediation, targeting audited FY25 results and ASX reinstatement by mid-2026.
Victor Sage
Victor Sage
26 Feb 2026
Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.
Sophie Babbage
Sophie Babbage
26 Feb 2026
CTI Logistics has reported a robust half-year performance with revenue climbing 7.6% and profit before tax soaring 64.2%, underpinned by operational efficiencies and strategic investments in Western Australia.
Victor Sage
Victor Sage
25 Feb 2026
Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.
Ada Torres
Ada Torres
25 Feb 2026
Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.
Ada Torres
Ada Torres
25 Feb 2026
Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Iress Limited reported a 7.4% revenue decline to $556.3 million for FY25 but achieved a 21.5% rise in profit before tax, declaring a fully franked final dividend of 13 cents per share. The company sharpened its focus on core Wealth and Trading software businesses while advancing sustainability and AI innovation.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.
Ada Torres
Ada Torres
25 Feb 2026
Acrow Ltd reported a robust 23% revenue increase in 1H FY26, driven by its expanding Industrial Access division, even as net profit fell 22% amid Queensland market softness. The company’s strategic investments and acquisitions position it well for future growth.
Victor Sage
Victor Sage
24 Feb 2026
Nuchev Limited reported a 12% increase in revenue to $12.38 million for the half-year ended December 2025, driven by growth in core products and offshore markets. However, the company’s net loss widened to $2.34 million amid ongoing investments in marketing, product development, and international expansion.
Victor Sage
Victor Sage
24 Feb 2026
333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.
Victor Sage
Victor Sage
24 Feb 2026